

**Olivier CHABRE**

Born September 27th 1960 in La Tronche (38) French citizen, married, four children.

e-mail [OlivierChabre@chu-grenoble.fr](mailto:OlivierChabre@chu-grenoble.fr)

Medical Order number : **38/6201**

**RPPS number 10003133815**

Professional adress :

[Service d'Endocrinologie-Diabétologie-Nutrition](#) (Pr PY Benhamou)

C.H.U. CS 10217 38043 Grenoble Cedex 09 Tel 0476765439 Fax 04767650 42

and

[Unité mixte INSERM-CEA-UJF U1036](#)

Institut de Recherches en Technologies et Sciences pour le Vivant

CEA-Grenoble, 17 Rue des Martyrs 38054 Grenoble Cedex 9

Tel 04 38 78 47 27 Fax 04 38 78 50 58

**Medical and scientific cursus**

- 2002** **Professor of Endocrinology (MD, PhD)** Université J. Fourier (UJF) **Grenoble**  
 CHU service Endocrinologie-Diabétologie-Nutrition **Grenoble**
- 1998-2002 **Praticien Hospitalier Universitaire** : UJF and CHU **Grenoble**
- 1993-1997 **Fellowship (MD)** UJF and CHU **Grenoble**
- 1992-1993 **INSERM post doc position** INSERM U 244 (Pr E.M.Chambaz) CEA **Grenoble**
- 1990-1992 **Post-doctoral research USA**  
 Dept. Pharmacology (Pr HR. Bourne) University of California **San Francisco**
- 1985-1990 **Resident** Hypertension Artérielle (Pr Safar) CHU Broussais **Paris**  
 Endocrinologie-Diabétologie x3 (Pr Bachelot), Cardiologie (Pr Denis), **Grenoble**  
 Médecine de la Reproduction (Pr Racinet) CHU **Grenoble**
- 1979-1985 **First and second cycle of Medical school**  
 Université Joseph Fourier **Grenoble**
- 1977-1979 **Biologie Mathématiques supérieures et spéciales** Lycée du Parc **Lyon**

**Diplomas**

- 1999 **Diploma of « Ability to lead research » (HDR)** UJF **Grenoble**  
[Endocrine tumors of the corticotroph axis](#)
- 1996 **PhD : Molecular and cellular Biology** UJF **Grenoble**  
[Activation of heterotrimeric G protein by receptor coupling or point mutation : its role in endocrine tumorigenesis.](#)
- 1990** **Medical Thesis (MD)** UJF **Grenoble**  
[Dépistage familial du syndrome de Néoplasies Endocriniennes Multiples de type 2A: marqueurs génotypiques et phénotypiques](#)
- 1989** **Master of Molecular and cellular Biology** UJF **Grenoble**  
[Oxygène et fonctions différenciées du cortex surrénalien](#)
- 1989** **Biochemical Endocrinology**  
 Mention Assez Bien Université Claude Bernard **Lyon**

**Society**

General Secretary of SFE (2013-2017)

Member of Endocrine Society, European Society for Endocrinology, COMETE (groupe de recherche sur les tumeurs surrénaliennes) ENSAT (European network for adrenal tumors)

**Selection 10 articles on adrenal tumors, out of 170 articles reported in PubMed**

Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, **Chabre O**, Young, J. Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas. **Eur J Endocrinol**. 6 janv 2022;186(2):K1-4..

Reda El Sayed S, Cristante J, Guyon L, Denis J, **Chabre O**, Cherradi N. MicroRNA Therapeutics in Cancer: Current Advances and Challenges. **Cancers** (Basel). 29 mai 2021;13(11).

Oreglia M, Sbiera S, Fassnacht M, Guyon L, Denis J, Cristante J, **Chabre O**, Cherradi N et al. Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. **Cancers** (Basel). 19 mars 2020;12(3).

Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R, ..**Chabre O**, ..et al. High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. **Eur J Endocrinol**. nov 2019;181(5):461-72.

Assié G, Jouinot A, Fassnacht M, Libé R, Garinet S, Jacob L, ..**Chabre O**, ..et al. Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. **JAMA Oncol**. 1 oct 2019;5(10):1440-7.

Agosta C, Laugier J, Guyon L, Denis J, Bertherat J, Libe R, ..**Chabre O** et Cherradi N MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. **Int J Cancer**. 2018;143(4):944-57.

Debillon E, Velayoudom-Cephise FL, Salenave S, Caron P, Chaffanjon P, Wagner T, ..Tabarin A et **Chabre O**. Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. **J Clin Endocrinol Metab**. 2015;100(12):4417-24.

Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, ...**Chabre O** ..et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. **Ann Oncol**. 2015;26(10):2119-25.

Nagy-Mignotte H, Shestaeva O, Vignoud L, Guillem P, Ruckly S, **Chabre O**, et al. Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. **J Thorac Oncol**. 2014;9(4):497-505.

**Chabre O**, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. **Endocr Relat Cancer**. 2013;20(4):579-94.

### **Experience in clinical trials : Investigator, with inclusion of patients in the following clinical trials**

ACROSTUDY (Acromegaly, Pfizer)  
 ACROPOLIS (Acromegaly, Ipsen)  
 ACROSPECT (Acromegaly, Novartis)  
 ADIUVO (Adrenal Cancer, ENS@T)  
 AGAL-005-99 (Fabry's disease, GENZYME)  
 FIRMACT (Adrenal Cancer, ENS@T)  
 C SOM 230 (Cushing's disease, Novartis)  
 GEREL-IMP (GH deficiency GHRH Ipsen)  
 HYPOCCS (GH deficiency Lilly)  
 KIMS (GH deficiency Pfizer)  
 MEGHA (GH deficiency Merck Serono)  
 NORDINET (GH deficiency Novo)  
 PRIMARA (Hyperparathyroidism Amgen)  
 PRIMARYS (Acromegaly Ipsen)  
 QOL Cushing (Quality of life Cushing, ERCUSYN)  
 SAPPORO (Acromegaly, University of Rouen/Novartis)

Grenoble, May 3<sup>rd</sup>, 2022

